Molecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical Trials

13-Jan-2012 - United Kingdom

Molecular Profiles announced the commencement of construction of a new manufacturing facility. This £9 million investment will allow Molecular Profiles to expand its current manufacturing capabilities while strengthening its existing expertise in the drug development field.

The new GMP facility, planned to open in late 2012, will provide an additional 30,000 square feet of space.  The investment marks a significant expansion of scale for the company with six new GMP suites, new laboratories and a clinical packing suite.  The new facility is designed to the latest specification, enabling flexibility of use and the manufacture of highly potent compounds up to OEB 4 level. Designed to handle a range of dosage forms including solids, liquids, semi-solids and inhaled products, the expanded capability allows Molecular Profiles to comprehensively cover phase I and II clinical trial requirements with manufacturing batch scale of up to 30kg.

The new build at Molecular Profiles’ site in Nottingham will complement the existing GMP facility and research laboratories, providing increased productivity across the company’s complete portfolio of drug development services.  The investment will enable expansion across all services including formulation development, polymorph and salt selection, analytical services, materials characterisation and clinical trial manufacturing. This significant investment further demonstrates Molecular Profiles’ commitment to providing its pharmaceutical customers a complete formulation and manufacturing capability in a single location.

The UK government has provided their support through the allocation of a regional growth fund grant of £1.6m. 

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Circassia Appoints Sir Richard Sykes as Chairman of the Board

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer

New findings about stem cells in the brain of patients with epilepsy

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases - BT-061 in clinical development for the treatment of RA and psoriasis

Cell Receptor Recycling Mechanism Discovery opens up New Class of Therapeutic Targets